Avalo Therapeutics Advances AVTX-010, Long-Acting Next-Gen Anti-IL-1β mAB With Potential For Development In HS And Additional Inflammatory Disorders; IND Submission Planned For H1 2027

Loading news article.

Avalo Therapeutics Advances AVTX-010, Long-Acting Next-Gen Anti-IL-1β mAB With Potential For Development In HS And Additional Inflammatory Disorders; IND Submission Planned For H1 2027 | WAPE

Avalo Therapeutics Advances AVTX-010, Long-Acting Next-Gen Anti-IL-1β mAB With Potential For Development In HS And Additional Inflammatory Disorders; IND Submission Planned For H1 2027

Article summary

Related companies

Comments —